Third Rock Launches Jounce Therapeutics with $47M
Third Rock Ventures announced Thursday the formation of Jounce Therapeutics, a company focused on developing cancer immunotherapies. Jounce is backed by a $47 million Series A financing round, Third Rock said in a written release.
14 February 2013•5 mins read
